title: [Agranulocytosis and transitory immune deficiency after fetal exposure to azathioprine and mesalazine].
authors.forename: H
authors.initials: H
authors.lastname: Cissoko
authors.forename: A P
authors.initials: AP
authors.lastname: Jonville-Béra
authors.forename: H
authors.initials: H
authors.lastname: Lenain
authors.forename: M F
authors.initials: MF
authors.lastname: Rivière
authors.forename: J
authors.initials: J
authors.lastname: Saugier
authors.forename: J L
authors.initials: JL
authors.lastname: Casanova
authors.forename: E
authors.initials: E
authors.lastname: Autret-Leca
mesh_terms: D000328:Adult; D000361:Agammaglobulinemia / Q000139:chemically induced*; D000380:Agranulocytosis / Q000139:chemically induced*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001379:Azathioprine / Q000009:adverse effects*; D016516:CD4-CD8 Ratio; D003424:Crohn Disease / Q000188:drug therapy; D005260:Female; D005333:Fetus / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D008431:Maternal-Fetal Exchange; D019804:Mesalamine / Q000009:adverse effects*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; D019804:Mesalamine; D001379:Azathioprine